SANUWAVE Health appointed LITHOMED as distributor for the orthoPACE® shockwave therapy device in Taiwan. SANUWAVE expects sales in this region to reach $0.5MM within three years.
orthoPACE has demonstrated safety and efficacy in the treatment of chronic tendonitis and joint pain, including diagnoses that commonly require surgery. In many indications, orthoPACE is reported to exhibit a success rate that is equal to or greater than that of surgery.
SANUWAVE Health appointed LITHOMED as distributor for the orthoPACE® shockwave therapy device in Taiwan. SANUWAVE expects sales in this region to reach $0.5MM within three years.
orthoPACE has demonstrated safety and efficacy in the treatment of chronic tendonitis and joint pain, including diagnoses that commonly require surgery....
SANUWAVE Health appointed LITHOMED as distributor for the orthoPACE® shockwave therapy device in Taiwan. SANUWAVE expects sales in this region to reach $0.5MM within three years.
orthoPACE has demonstrated safety and efficacy in the treatment of chronic tendonitis and joint pain, including diagnoses that commonly require surgery. In many indications, orthoPACE is reported to exhibit a success rate that is equal to or greater than that of surgery.
Copy to clipboard 
